Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schepens Eye Research Institute

Division of Massachusetts Eye & Ear Infirmary

Latest From Sylentis SA

Pipeline Watch: Top-Line Fremanezumab, Ramucirumab, Bictegravir Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry (01/2012)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Yondelis drives Zeltia Group's biopharmaceutical business

Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.

Cancer Neurology

Yondelis drives Zeltia Group sales

Yondelis (trabectedin), for the treatment of metastatic or advanced soft tissue sarcoma, drove business for the Spanish biotech group Zeltiaduring the first nine months of 2008.

Cancer Neurology
See All